Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell presents Moditope data at prestigious cancer conference

Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday
conference hall
Data showed that Modi-1 had an anti-tumour effect on pancreatic, lung, ovarian and melanoma cancer models

Cancer drug developer Scancell Holdings PLC (LON:SCLP) presented the latest data from its Moditope platform at the International Cancer Immunotherapy conference in Germany – one of the most prestigious meetings in the industry’s calendar.

Moditope stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.

The AIM-quoted firm’s chief scientific officer Lindy Durrant presented two posters at the conference on Friday.

LOOK: Take a look at the two posters

The data showed that Modi-1 – the lead product from the platform – induced strong anti-tumour immunity in pancreatic, lung, ovarian and melanoma cancer models with up to 100% survival.

“Our poster in collaboration with ISA Pharmaceuticals showed that Modi-1 conjugated to synthetic TLR1/2 agonists generated an anti-tumour response at up to 100-fold lower doses than Modi-1 alone and that these conjugated peptides induced a memory response against tumour re-challenge,” said Durrant.

“These results suggest that Modi-1 conjugated directly to TLR agonists could be a powerful new approach to the treatment of cancer.”

Shares rose 0.9% to 14.12p.

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Newswire
January 31 2017

Related Articles

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use